| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 106 | 2025 | 1242 | 8.740 |
Why?
|
| Obesity | 140 | 2024 | 2885 | 8.400 |
Why?
|
| Cardiovascular Diseases | 123 | 2024 | 2008 | 6.370 |
Why?
|
| Blood Pressure | 114 | 2025 | 1736 | 5.800 |
Why?
|
| Body Mass Index | 124 | 2024 | 2274 | 5.330 |
Why?
|
| Hyperlipoproteinemia Type II | 14 | 2024 | 34 | 4.990 |
Why?
|
| Child | 391 | 2024 | 20962 | 4.370 |
Why?
|
| Adolescent | 382 | 2025 | 20451 | 4.030 |
Why?
|
| Dyslipidemias | 23 | 2024 | 177 | 3.160 |
Why?
|
| Pediatric Obesity | 19 | 2021 | 573 | 2.970 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 22 | 2025 | 83 | 2.960 |
Why?
|
| Obesity, Morbid | 22 | 2019 | 242 | 2.920 |
Why?
|
| Mass Screening | 22 | 2024 | 1192 | 2.910 |
Why?
|
| Humans | 627 | 2025 | 129847 | 2.890 |
Why?
|
| Lipids | 35 | 2024 | 628 | 2.790 |
Why?
|
| Metabolic Syndrome | 29 | 2015 | 340 | 2.760 |
Why?
|
| Cholesterol, LDL | 33 | 2024 | 358 | 2.700 |
Why?
|
| Pediatrics | 37 | 2023 | 1074 | 2.690 |
Why?
|
| Hypercholesterolemia | 15 | 2024 | 102 | 2.320 |
Why?
|
| Adiposity | 17 | 2022 | 504 | 2.280 |
Why?
|
| Hypertrophy, Left Ventricular | 28 | 2021 | 127 | 2.240 |
Why?
|
| Atherosclerosis | 23 | 2023 | 402 | 2.170 |
Why?
|
| Female | 388 | 2025 | 68829 | 2.140 |
Why?
|
| Risk Factors | 143 | 2025 | 9801 | 2.140 |
Why?
|
| Diet | 28 | 2018 | 1212 | 2.060 |
Why?
|
| Blood Pressure Determination | 20 | 2025 | 148 | 2.050 |
Why?
|
| Pain, Postoperative | 11 | 2024 | 247 | 1.960 |
Why?
|
| Primary Prevention | 8 | 2020 | 190 | 1.930 |
Why?
|
| Male | 315 | 2025 | 63759 | 1.840 |
Why?
|
| Adipose Tissue | 20 | 2022 | 594 | 1.820 |
Why?
|
| Vascular Stiffness | 18 | 2025 | 467 | 1.770 |
Why?
|
| Feeding Behavior | 17 | 2023 | 626 | 1.730 |
Why?
|
| Child, Preschool | 129 | 2024 | 10522 | 1.680 |
Why?
|
| Prevalence | 62 | 2021 | 2564 | 1.660 |
Why?
|
| Cholesterol | 21 | 2024 | 412 | 1.550 |
Why?
|
| Diabetes Mellitus, Type 2 | 40 | 2024 | 2444 | 1.540 |
Why?
|
| Anticholesteremic Agents | 7 | 2024 | 150 | 1.520 |
Why?
|
| Adult | 210 | 2024 | 35634 | 1.500 |
Why?
|
| Exercise | 27 | 2019 | 1934 | 1.460 |
Why?
|
| Infant Formula | 3 | 2019 | 74 | 1.450 |
Why?
|
| Body Composition | 18 | 2018 | 649 | 1.380 |
Why?
|
| Practice Guidelines as Topic | 25 | 2021 | 1514 | 1.370 |
Why?
|
| Insulin Resistance | 22 | 2022 | 1168 | 1.370 |
Why?
|
| American Heart Association | 27 | 2022 | 300 | 1.340 |
Why?
|
| Weight Loss | 21 | 2019 | 740 | 1.340 |
Why?
|
| Diabetes Mellitus, Type 1 | 39 | 2023 | 3630 | 1.310 |
Why?
|
| Antihypertensive Agents | 14 | 2024 | 485 | 1.300 |
Why?
|
| Carotid Intima-Media Thickness | 11 | 2022 | 90 | 1.300 |
Why?
|
| Longitudinal Studies | 55 | 2024 | 2724 | 1.290 |
Why?
|
| Body Constitution | 17 | 2007 | 53 | 1.280 |
Why?
|
| Age Factors | 58 | 2024 | 3161 | 1.280 |
Why?
|
| Life Style | 19 | 2019 | 462 | 1.260 |
Why?
|
| United States | 108 | 2024 | 13913 | 1.240 |
Why?
|
| Body Weight | 25 | 2019 | 947 | 1.230 |
Why?
|
| Carotid Arteries | 11 | 2015 | 196 | 1.210 |
Why?
|
| Echocardiography | 48 | 2021 | 636 | 1.210 |
Why?
|
| Double-Blind Method | 25 | 2024 | 1877 | 1.190 |
Why?
|
| Puberty | 14 | 2018 | 143 | 1.170 |
Why?
|
| Hypolipidemic Agents | 7 | 2012 | 92 | 1.150 |
Why?
|
| Gastric Bypass | 12 | 2017 | 108 | 1.150 |
Why?
|
| Diet, Reducing | 10 | 2017 | 87 | 1.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 10 | 2013 | 340 | 1.120 |
Why?
|
| Diclofenac | 6 | 2013 | 15 | 1.110 |
Why?
|
| Hyperlipidemias | 6 | 2012 | 127 | 1.090 |
Why?
|
| Ventricular Dysfunction, Left | 11 | 2020 | 385 | 1.080 |
Why?
|
| Eating | 8 | 2023 | 372 | 1.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 756 | 1.070 |
Why?
|
| Heart Rate | 21 | 2019 | 804 | 1.070 |
Why?
|
| Sleep Apnea Syndromes | 7 | 2008 | 82 | 1.060 |
Why?
|
| White Coat Hypertension | 3 | 2025 | 7 | 1.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 2024 | 430 | 1.050 |
Why?
|
| Overweight | 13 | 2019 | 531 | 1.050 |
Why?
|
| Energy Intake | 19 | 2020 | 462 | 1.050 |
Why?
|
| Cholesterol, HDL | 19 | 2023 | 205 | 1.020 |
Why?
|
| Regression Analysis | 36 | 2014 | 998 | 1.020 |
Why?
|
| Risk Reduction Behavior | 13 | 2014 | 209 | 1.020 |
Why?
|
| Bariatric Surgery | 11 | 2019 | 197 | 1.010 |
Why?
|
| Heart Defects, Congenital | 13 | 2019 | 796 | 0.990 |
Why?
|
| Young Adult | 78 | 2024 | 12467 | 0.980 |
Why?
|
| Risk Assessment | 24 | 2022 | 3269 | 0.950 |
Why?
|
| Feeding and Eating Disorders | 9 | 2005 | 147 | 0.920 |
Why?
|
| Health Promotion | 12 | 2019 | 718 | 0.920 |
Why?
|
| Diabetes Complications | 9 | 2019 | 224 | 0.920 |
Why?
|
| Health Status | 7 | 2016 | 758 | 0.910 |
Why?
|
| Ventricular Function, Left | 20 | 2006 | 529 | 0.900 |
Why?
|
| Kidney Failure, Chronic | 10 | 2008 | 546 | 0.900 |
Why?
|
| Motor Activity | 14 | 2018 | 684 | 0.890 |
Why?
|
| Systole | 18 | 2024 | 191 | 0.880 |
Why?
|
| Cardiovascular System | 6 | 2021 | 136 | 0.880 |
Why?
|
| Infant | 69 | 2019 | 9018 | 0.860 |
Why?
|
| Acute Pain | 4 | 2018 | 48 | 0.860 |
Why?
|
| Prehypertension | 3 | 2012 | 27 | 0.850 |
Why?
|
| Fasting | 8 | 2020 | 268 | 0.830 |
Why?
|
| Prospective Studies | 44 | 2024 | 7158 | 0.820 |
Why?
|
| Dietary Carbohydrates | 9 | 2015 | 152 | 0.820 |
Why?
|
| Physical Fitness | 6 | 2013 | 203 | 0.820 |
Why?
|
| Sleep Apnea, Obstructive | 10 | 2020 | 279 | 0.810 |
Why?
|
| Ohio | 25 | 2016 | 152 | 0.810 |
Why?
|
| Proprotein Convertase 9 | 2 | 2022 | 68 | 0.800 |
Why?
|
| Cardiovascular Agents | 2 | 2014 | 157 | 0.800 |
Why?
|
| Child Behavior | 8 | 2020 | 236 | 0.790 |
Why?
|
| Adolescent Behavior | 10 | 2020 | 507 | 0.790 |
Why?
|
| Arteriosclerosis | 11 | 2013 | 89 | 0.780 |
Why?
|
| Pulse Wave Analysis | 11 | 2023 | 248 | 0.780 |
Why?
|
| Bulimia Nervosa | 3 | 2007 | 19 | 0.770 |
Why?
|
| Triglycerides | 25 | 2024 | 528 | 0.770 |
Why?
|
| Heart Ventricles | 23 | 2014 | 781 | 0.770 |
Why?
|
| Follow-Up Studies | 38 | 2020 | 4896 | 0.770 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 7 | 2018 | 92 | 0.760 |
Why?
|
| Cohort Studies | 47 | 2024 | 5444 | 0.750 |
Why?
|
| Naproxen | 4 | 2016 | 17 | 0.750 |
Why?
|
| Diastole | 18 | 2020 | 148 | 0.750 |
Why?
|
| Waist Circumference | 16 | 2015 | 138 | 0.730 |
Why?
|
| Exercise Test | 16 | 2018 | 614 | 0.730 |
Why?
|
| Treatment Outcome | 30 | 2024 | 10241 | 0.730 |
Why?
|
| Child Health | 3 | 2020 | 147 | 0.730 |
Why?
|
| Spiro Compounds | 2 | 2018 | 11 | 0.720 |
Why?
|
| Anthropometry | 16 | 2018 | 204 | 0.710 |
Why?
|
| Heart | 13 | 2023 | 645 | 0.700 |
Why?
|
| Laparoscopy | 4 | 2017 | 447 | 0.700 |
Why?
|
| Maternal Health | 1 | 2021 | 45 | 0.690 |
Why?
|
| Sex Factors | 28 | 2017 | 1973 | 0.690 |
Why?
|
| Coronary Aneurysm | 3 | 2018 | 14 | 0.680 |
Why?
|
| Dysmenorrhea | 3 | 2009 | 5 | 0.670 |
Why?
|
| Depression | 8 | 2012 | 1323 | 0.660 |
Why?
|
| Absorptiometry, Photon | 14 | 2018 | 247 | 0.650 |
Why?
|
| Circadian Rhythm | 6 | 2014 | 416 | 0.640 |
Why?
|
| Incidence | 23 | 2024 | 2646 | 0.640 |
Why?
|
| Blood Glucose | 20 | 2020 | 2103 | 0.640 |
Why?
|
| Fruit | 8 | 2020 | 131 | 0.630 |
Why?
|
| Analgesics | 2 | 2018 | 194 | 0.630 |
Why?
|
| Reference Values | 28 | 2017 | 796 | 0.620 |
Why?
|
| Heterozygote | 1 | 2020 | 271 | 0.620 |
Why?
|
| Oil and Gas Fields | 1 | 2019 | 31 | 0.620 |
Why?
|
| Infant, Newborn | 37 | 2019 | 5772 | 0.620 |
Why?
|
| Body Height | 14 | 2018 | 192 | 0.610 |
Why?
|
| Food | 4 | 2016 | 156 | 0.610 |
Why?
|
| Deafness | 2 | 2018 | 80 | 0.610 |
Why?
|
| Biomarkers | 12 | 2025 | 3971 | 0.610 |
Why?
|
| Child Development | 5 | 2016 | 459 | 0.590 |
Why?
|
| Maternal Exposure | 3 | 2019 | 177 | 0.590 |
Why?
|
| Nervous System Malformations | 1 | 2018 | 38 | 0.590 |
Why?
|
| Adenoidectomy | 4 | 2020 | 65 | 0.590 |
Why?
|
| Phenols | 2 | 2009 | 96 | 0.580 |
Why?
|
| Predictive Value of Tests | 17 | 2017 | 1951 | 0.580 |
Why?
|
| Walk Test | 1 | 2018 | 70 | 0.580 |
Why?
|
| Internationality | 3 | 2015 | 150 | 0.570 |
Why?
|
| Advisory Committees | 2 | 2016 | 216 | 0.570 |
Why?
|
| Vegetables | 8 | 2020 | 147 | 0.570 |
Why?
|
| Diet Records | 14 | 2020 | 80 | 0.570 |
Why?
|
| Aortic Coarctation | 7 | 2019 | 83 | 0.570 |
Why?
|
| Diabetic Angiopathies | 8 | 2019 | 261 | 0.570 |
Why?
|
| Preventive Health Services | 3 | 2017 | 145 | 0.570 |
Why?
|
| Morbidity | 4 | 2017 | 302 | 0.570 |
Why?
|
| Tooth Extraction | 5 | 2016 | 24 | 0.560 |
Why?
|
| Adiponectin | 8 | 2012 | 236 | 0.560 |
Why?
|
| Middle Aged | 65 | 2024 | 31177 | 0.560 |
Why?
|
| Tonsillectomy | 4 | 2020 | 82 | 0.550 |
Why?
|
| Sleep | 7 | 2019 | 689 | 0.550 |
Why?
|
| Time Factors | 33 | 2020 | 6550 | 0.550 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2017 | 14 | 0.550 |
Why?
|
| Decision Making | 2 | 2014 | 864 | 0.540 |
Why?
|
| Smoking | 12 | 2024 | 1502 | 0.540 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 345 | 0.540 |
Why?
|
| Anti-Obesity Agents | 5 | 2018 | 53 | 0.530 |
Why?
|
| Cardiology | 7 | 2019 | 266 | 0.530 |
Why?
|
| Air Pollution | 1 | 2019 | 218 | 0.520 |
Why?
|
| Plasma Gases | 3 | 2023 | 7 | 0.520 |
Why?
|
| Cross-Sectional Studies | 38 | 2024 | 5085 | 0.520 |
Why?
|
| Diet, Carbohydrate-Restricted | 2 | 2017 | 32 | 0.510 |
Why?
|
| Adolescent Development | 3 | 2012 | 84 | 0.510 |
Why?
|
| Nanotechnology | 3 | 2016 | 121 | 0.510 |
Why?
|
| Intra-Abdominal Fat | 2 | 2015 | 88 | 0.510 |
Why?
|
| Graphite | 1 | 2016 | 11 | 0.510 |
Why?
|
| Brachial Artery | 5 | 2013 | 192 | 0.510 |
Why?
|
| Gastroplasty | 3 | 2005 | 29 | 0.510 |
Why?
|
| Ketorolac | 2 | 2013 | 20 | 0.500 |
Why?
|
| Biomedical Research | 6 | 2019 | 640 | 0.500 |
Why?
|
| Beverages | 3 | 2017 | 68 | 0.500 |
Why?
|
| Accelerometry | 2 | 2014 | 93 | 0.500 |
Why?
|
| Population Surveillance | 4 | 2019 | 439 | 0.500 |
Why?
|
| Bulimia | 3 | 2006 | 24 | 0.500 |
Why?
|
| Monitoring, Physiologic | 4 | 2013 | 266 | 0.500 |
Why?
|
| Self Disclosure | 2 | 2006 | 62 | 0.500 |
Why?
|
| Caloric Restriction | 2 | 2009 | 111 | 0.500 |
Why?
|
| Pain Measurement | 6 | 2024 | 510 | 0.480 |
Why?
|
| Central Nervous System Stimulants | 2 | 2009 | 154 | 0.480 |
Why?
|
| Body Image | 3 | 2004 | 84 | 0.480 |
Why?
|
| Carbonated Beverages | 2 | 2006 | 16 | 0.480 |
Why?
|
| Hallux Valgus | 4 | 2016 | 9 | 0.470 |
Why?
|
| Indoles | 1 | 2018 | 387 | 0.470 |
Why?
|
| Nutritional Requirements | 3 | 2012 | 77 | 0.470 |
Why?
|
| Wind | 1 | 2014 | 12 | 0.470 |
Why?
|
| Physician's Role | 3 | 2016 | 206 | 0.470 |
Why?
|
| Hearing Loss | 1 | 2018 | 209 | 0.460 |
Why?
|
| Nanostructures | 1 | 2016 | 100 | 0.460 |
Why?
|
| Kidney Transplantation | 5 | 2019 | 670 | 0.460 |
Why?
|
| Caffeine | 2 | 2006 | 62 | 0.460 |
Why?
|
| Case-Control Studies | 15 | 2019 | 3384 | 0.460 |
Why?
|
| Severity of Illness Index | 20 | 2017 | 2739 | 0.450 |
Why?
|
| Rain | 1 | 2014 | 44 | 0.450 |
Why?
|
| Health Status Indicators | 3 | 2020 | 166 | 0.450 |
Why?
|
| Child Welfare | 7 | 2012 | 210 | 0.450 |
Why?
|
| Micronutrients | 2 | 2012 | 88 | 0.440 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2017 | 235 | 0.440 |
Why?
|
| Ventricular Remodeling | 4 | 2020 | 256 | 0.440 |
Why?
|
| Diabetes Mellitus | 6 | 2016 | 1003 | 0.440 |
Why?
|
| Schools | 4 | 2017 | 443 | 0.440 |
Why?
|
| Orthopedic Procedures | 3 | 2016 | 209 | 0.440 |
Why?
|
| Societies, Medical | 9 | 2020 | 759 | 0.440 |
Why?
|
| Comorbidity | 15 | 2017 | 1551 | 0.440 |
Why?
|
| Faculty, Medical | 4 | 2012 | 269 | 0.430 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 122 | 0.430 |
Why?
|
| Disease Management | 4 | 2012 | 592 | 0.430 |
Why?
|
| Multivariate Analysis | 11 | 2021 | 1501 | 0.430 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 4 | 2024 | 21 | 0.430 |
Why?
|
| Regional Blood Flow | 2 | 2015 | 463 | 0.430 |
Why?
|
| Public Health | 6 | 2014 | 487 | 0.420 |
Why?
|
| Walking | 1 | 2018 | 500 | 0.420 |
Why?
|
| Ibuprofen | 2 | 2016 | 81 | 0.420 |
Why?
|
| Tramadol | 2 | 2024 | 10 | 0.420 |
Why?
|
| Celecoxib | 6 | 2024 | 39 | 0.420 |
Why?
|
| Age of Onset | 15 | 2013 | 494 | 0.410 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2018 | 2016 | 0.410 |
Why?
|
| Patient Compliance | 6 | 2014 | 568 | 0.410 |
Why?
|
| Attitude to Health | 5 | 2006 | 433 | 0.410 |
Why?
|
| Dietary Fats | 10 | 2012 | 303 | 0.410 |
Why?
|
| Coronary Disease | 9 | 2011 | 385 | 0.410 |
Why?
|
| Growth Charts | 1 | 2012 | 14 | 0.400 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2009 | 80 | 0.400 |
Why?
|
| Analgesics, Opioid | 6 | 2024 | 925 | 0.400 |
Why?
|
| Finland | 10 | 2024 | 90 | 0.390 |
Why?
|
| Nutrition Surveys | 6 | 2015 | 260 | 0.390 |
Why?
|
| Parents | 8 | 2019 | 1319 | 0.390 |
Why?
|
| Disinfection | 2 | 2024 | 117 | 0.390 |
Why?
|
| Family | 4 | 2007 | 646 | 0.390 |
Why?
|
| Social Justice | 3 | 2023 | 76 | 0.380 |
Why?
|
| Metabolic Diseases | 3 | 2016 | 104 | 0.370 |
Why?
|
| Disease Progression | 10 | 2019 | 2628 | 0.370 |
Why?
|
| Forecasting | 6 | 2020 | 361 | 0.370 |
Why?
|
| Vascular Resistance | 6 | 2011 | 371 | 0.370 |
Why?
|
| Temperature | 1 | 2014 | 635 | 0.370 |
Why?
|
| Health Behavior | 10 | 2020 | 743 | 0.370 |
Why?
|
| Ductus Arteriosus, Patent | 4 | 2009 | 49 | 0.370 |
Why?
|
| Hemodynamics | 14 | 2012 | 1094 | 0.360 |
Why?
|
| Logistic Models | 10 | 2019 | 1989 | 0.360 |
Why?
|
| Health Services Accessibility | 2 | 2016 | 903 | 0.360 |
Why?
|
| Career Mobility | 1 | 2012 | 68 | 0.360 |
Why?
|
| Food Preferences | 3 | 2011 | 116 | 0.360 |
Why?
|
| Breast Feeding | 3 | 2016 | 424 | 0.360 |
Why?
|
| Demography | 5 | 2016 | 279 | 0.360 |
Why?
|
| Cross Infection | 3 | 2022 | 219 | 0.360 |
Why?
|
| Tunica Media | 5 | 2011 | 38 | 0.360 |
Why?
|
| Dietary Sucrose | 3 | 2015 | 48 | 0.360 |
Why?
|
| Sexual Maturation | 5 | 2018 | 52 | 0.350 |
Why?
|
| Surveys and Questionnaires | 19 | 2017 | 5437 | 0.350 |
Why?
|
| Cyclobutanes | 2 | 2007 | 6 | 0.340 |
Why?
|
| Polysomnography | 10 | 2012 | 178 | 0.340 |
Why?
|
| Nervous System Diseases | 2 | 2023 | 252 | 0.340 |
Why?
|
| Appetite Depressants | 2 | 2007 | 18 | 0.340 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2022 | 221 | 0.330 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 483 | 0.330 |
Why?
|
| Family Health | 5 | 2012 | 198 | 0.330 |
Why?
|
| Mothers | 3 | 2012 | 731 | 0.330 |
Why?
|
| Environmental Microbiology | 3 | 2015 | 48 | 0.320 |
Why?
|
| Self Concept | 7 | 2007 | 240 | 0.320 |
Why?
|
| Hyperinsulinism | 5 | 2011 | 119 | 0.320 |
Why?
|
| Methylphenidate | 1 | 2009 | 36 | 0.310 |
Why?
|
| Lipoproteins | 10 | 2023 | 172 | 0.310 |
Why?
|
| Poloxamer | 1 | 2009 | 12 | 0.310 |
Why?
|
| Evidence-Based Medicine | 8 | 2012 | 716 | 0.310 |
Why?
|
| Colloids | 2 | 2015 | 58 | 0.310 |
Why?
|
| Sulfonamides | 4 | 2013 | 497 | 0.310 |
Why?
|
| Sweetening Agents | 1 | 2009 | 41 | 0.310 |
Why?
|
| Heart Murmurs | 1 | 2009 | 14 | 0.310 |
Why?
|
| Energy Metabolism | 6 | 2006 | 875 | 0.310 |
Why?
|
| Neurotransmitter Agents | 1 | 2009 | 81 | 0.310 |
Why?
|
| Anorexia Nervosa | 4 | 2006 | 84 | 0.310 |
Why?
|
| Colorado | 11 | 2019 | 4410 | 0.310 |
Why?
|
| Oxycodone | 1 | 2009 | 43 | 0.310 |
Why?
|
| Diabetes, Gestational | 4 | 2018 | 308 | 0.310 |
Why?
|
| Insulin | 12 | 2020 | 2330 | 0.300 |
Why?
|
| Bone Density | 3 | 2010 | 463 | 0.300 |
Why?
|
| Health Surveys | 9 | 2020 | 495 | 0.300 |
Why?
|
| Oligomenorrhea | 3 | 2015 | 8 | 0.300 |
Why?
|
| Aged | 33 | 2024 | 22107 | 0.300 |
Why?
|
| Pyrazoles | 4 | 2013 | 403 | 0.300 |
Why?
|
| Sodium, Dietary | 7 | 2015 | 37 | 0.300 |
Why?
|
| Bariatrics | 2 | 2005 | 5 | 0.290 |
Why?
|
| Racism | 2 | 2020 | 128 | 0.290 |
Why?
|
| Tunica Intima | 5 | 2011 | 84 | 0.290 |
Why?
|
| Pregnancy | 15 | 2021 | 6423 | 0.290 |
Why?
|
| Milk | 1 | 2009 | 122 | 0.290 |
Why?
|
| Uric Acid | 1 | 2009 | 161 | 0.290 |
Why?
|
| Thinness | 4 | 2015 | 89 | 0.290 |
Why?
|
| Hand Strength | 1 | 2009 | 113 | 0.290 |
Why?
|
| Eosinophilia-Myalgia Syndrome | 3 | 1996 | 3 | 0.290 |
Why?
|
| Genetic Testing | 3 | 2021 | 422 | 0.290 |
Why?
|
| Birth Weight | 4 | 2018 | 505 | 0.280 |
Why?
|
| Growth Hormone | 1 | 2008 | 100 | 0.280 |
Why?
|
| Diet, Fat-Restricted | 4 | 2007 | 80 | 0.280 |
Why?
|
| Growth Disorders | 1 | 2008 | 81 | 0.280 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2009 | 122 | 0.280 |
Why?
|
| Linear Models | 10 | 2013 | 822 | 0.280 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2019 | 567 | 0.280 |
Why?
|
| Cardiac Output | 9 | 2005 | 157 | 0.280 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2008 | 84 | 0.280 |
Why?
|
| Cost-Benefit Analysis | 4 | 2019 | 569 | 0.270 |
Why?
|
| Hypertension, Pulmonary | 3 | 2017 | 1897 | 0.270 |
Why?
|
| Heart Atria | 3 | 2010 | 129 | 0.270 |
Why?
|
| Myocardial Contraction | 14 | 2005 | 335 | 0.270 |
Why?
|
| Australia | 7 | 2024 | 243 | 0.270 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 187 | 0.270 |
Why?
|
| Sleep Wake Disorders | 3 | 2018 | 255 | 0.270 |
Why?
|
| Transition to Adult Care | 3 | 2019 | 82 | 0.260 |
Why?
|
| Counseling | 3 | 2017 | 386 | 0.260 |
Why?
|
| Nitrites | 2 | 2024 | 83 | 0.260 |
Why?
|
| Dairy Products | 3 | 2012 | 36 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 1368 | 0.260 |
Why?
|
| Apolipoproteins B | 4 | 2014 | 43 | 0.260 |
Why?
|
| Pediatricians | 2 | 2019 | 130 | 0.260 |
Why?
|
| Health Services | 2 | 2005 | 99 | 0.260 |
Why?
|
| Osteotomy | 2 | 2024 | 102 | 0.260 |
Why?
|
| Acetaminophen | 1 | 2009 | 248 | 0.260 |
Why?
|
| Child Nutritional Physiological Phenomena | 6 | 2016 | 104 | 0.250 |
Why?
|
| Age Distribution | 7 | 2015 | 372 | 0.250 |
Why?
|
| Tryptophan | 3 | 1996 | 177 | 0.250 |
Why?
|
| Menarche | 5 | 2018 | 59 | 0.250 |
Why?
|
| Weaning | 1 | 2006 | 48 | 0.250 |
Why?
|
| Sensitivity and Specificity | 11 | 2021 | 1847 | 0.250 |
Why?
|
| Parent-Child Relations | 2 | 2004 | 259 | 0.250 |
Why?
|
| Peripheral Arterial Disease | 1 | 2012 | 458 | 0.250 |
Why?
|
| Quality of Health Care | 2 | 2016 | 610 | 0.250 |
Why?
|
| Guidelines as Topic | 5 | 2019 | 264 | 0.250 |
Why?
|
| Organ Size | 5 | 2010 | 456 | 0.250 |
Why?
|
| Nutrition Policy | 6 | 2017 | 57 | 0.250 |
Why?
|
| Nutrition Assessment | 3 | 2015 | 86 | 0.250 |
Why?
|
| Escherichia coli | 2 | 2024 | 766 | 0.250 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 6 | 2016 | 26 | 0.240 |
Why?
|
| Maternal Behavior | 1 | 2006 | 74 | 0.240 |
Why?
|
| Research | 4 | 2017 | 420 | 0.240 |
Why?
|
| Dyssomnias | 1 | 2005 | 3 | 0.240 |
Why?
|
| Research Design | 5 | 2018 | 1045 | 0.240 |
Why?
|
| Myocardium | 3 | 2008 | 983 | 0.240 |
Why?
|
| Organ Transplantation | 2 | 2019 | 228 | 0.240 |
Why?
|
| Aging | 8 | 2009 | 1774 | 0.240 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2009 | 397 | 0.240 |
Why?
|
| Bronchopulmonary Dysplasia | 2 | 2009 | 378 | 0.230 |
Why?
|
| Cluster Analysis | 3 | 2015 | 483 | 0.230 |
Why?
|
| Phosphorus | 1 | 2005 | 92 | 0.230 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2022 | 35 | 0.230 |
Why?
|
| Hydrogen Peroxide | 2 | 2023 | 317 | 0.230 |
Why?
|
| Beriberi | 1 | 2004 | 2 | 0.230 |
Why?
|
| Somatoform Disorders | 1 | 2004 | 41 | 0.230 |
Why?
|
| Stress, Psychological | 4 | 2006 | 1070 | 0.230 |
Why?
|
| Psychology, Child | 1 | 2004 | 38 | 0.230 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2005 | 98 | 0.230 |
Why?
|
| Self Report | 3 | 2020 | 800 | 0.230 |
Why?
|
| Epigenesis, Genetic | 1 | 2009 | 615 | 0.230 |
Why?
|
| Psychology, Adolescent | 1 | 2004 | 65 | 0.220 |
Why?
|
| Mental Recall | 2 | 2013 | 191 | 0.220 |
Why?
|
| Kidney Diseases | 4 | 2007 | 382 | 0.220 |
Why?
|
| Calcium, Dietary | 5 | 2007 | 56 | 0.220 |
Why?
|
| Pain | 2 | 2009 | 791 | 0.220 |
Why?
|
| Models, Statistical | 6 | 2013 | 624 | 0.220 |
Why?
|
| Play and Playthings | 1 | 2004 | 34 | 0.220 |
Why?
|
| Brain | 4 | 2018 | 2677 | 0.220 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2017 | 260 | 0.220 |
Why?
|
| Medical History Taking | 2 | 2022 | 118 | 0.220 |
Why?
|
| Weight Gain | 5 | 2018 | 510 | 0.220 |
Why?
|
| Patient Dropouts | 1 | 2004 | 64 | 0.210 |
Why?
|
| Hospitals | 4 | 2022 | 649 | 0.210 |
Why?
|
| Program Evaluation | 2 | 2007 | 878 | 0.210 |
Why?
|
| Postoperative Complications | 10 | 2006 | 2481 | 0.210 |
Why?
|
| Congresses as Topic | 2 | 2019 | 216 | 0.210 |
Why?
|
| Primary Health Care | 5 | 2015 | 1687 | 0.210 |
Why?
|
| Retrospective Studies | 33 | 2019 | 14553 | 0.210 |
Why?
|
| Life Change Events | 1 | 2004 | 149 | 0.210 |
Why?
|
| Abdominal Cavity | 1 | 2003 | 5 | 0.210 |
Why?
|
| Myocardial Ischemia | 4 | 2008 | 259 | 0.210 |
Why?
|
| Bunion | 2 | 2024 | 3 | 0.210 |
Why?
|
| Meat | 4 | 2012 | 93 | 0.200 |
Why?
|
| Quality of Life | 4 | 2009 | 2695 | 0.200 |
Why?
|
| Heart Diseases | 4 | 2008 | 352 | 0.200 |
Why?
|
| Indomethacin | 2 | 2013 | 79 | 0.200 |
Why?
|
| Hypertriglyceridemia | 3 | 2011 | 39 | 0.200 |
Why?
|
| Skinfold Thickness | 6 | 2009 | 46 | 0.200 |
Why?
|
| Varicose Ulcer | 1 | 2002 | 4 | 0.200 |
Why?
|
| Burns | 5 | 1994 | 292 | 0.200 |
Why?
|
| Renal Dialysis | 6 | 2005 | 423 | 0.200 |
Why?
|
| Education, Medical, Graduate | 3 | 2014 | 443 | 0.200 |
Why?
|
| Stroke | 7 | 2019 | 1072 | 0.200 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 3 | 2019 | 103 | 0.190 |
Why?
|
| Phantoms, Imaging | 1 | 2003 | 137 | 0.190 |
Why?
|
| Guideline Adherence | 4 | 2017 | 527 | 0.190 |
Why?
|
| Bacteriophages | 1 | 2023 | 86 | 0.190 |
Why?
|
| Saliva | 1 | 2023 | 212 | 0.190 |
Why?
|
| Food Safety | 2 | 2019 | 18 | 0.190 |
Why?
|
| Reference Standards | 5 | 2023 | 176 | 0.190 |
Why?
|
| Health Policy | 3 | 2013 | 354 | 0.190 |
Why?
|
| Masked Hypertension | 1 | 2021 | 4 | 0.190 |
Why?
|
| Research Personnel | 1 | 2023 | 156 | 0.190 |
Why?
|
| Carotid Artery Diseases | 2 | 2013 | 64 | 0.190 |
Why?
|
| Reproducibility of Results | 11 | 2016 | 3089 | 0.190 |
Why?
|
| Clinical Trials as Topic | 7 | 2007 | 1005 | 0.190 |
Why?
|
| Retinal Vessels | 2 | 1993 | 66 | 0.190 |
Why?
|
| Nicardipine | 1 | 2001 | 6 | 0.180 |
Why?
|
| Arteries | 4 | 2010 | 266 | 0.180 |
Why?
|
| Contraceptives, Oral | 1 | 2001 | 38 | 0.180 |
Why?
|
| Nifedipine | 1 | 2001 | 29 | 0.180 |
Why?
|
| Fatty Liver | 3 | 2009 | 230 | 0.180 |
Why?
|
| Patient Selection | 4 | 2006 | 660 | 0.180 |
Why?
|
| Terminology as Topic | 3 | 2017 | 204 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2012 | 1284 | 0.180 |
Why?
|
| Benchmarking | 1 | 2022 | 176 | 0.180 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2001 | 15 | 0.180 |
Why?
|
| Gastroenterology | 2 | 2017 | 177 | 0.180 |
Why?
|
| High Fructose Corn Syrup | 2 | 2018 | 8 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2012 | 2271 | 0.180 |
Why?
|
| Whole Grains | 1 | 2020 | 3 | 0.180 |
Why?
|
| Research Support as Topic | 2 | 2019 | 112 | 0.180 |
Why?
|
| Risk | 8 | 2012 | 860 | 0.170 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2001 | 43 | 0.170 |
Why?
|
| Sex Characteristics | 7 | 2006 | 735 | 0.170 |
Why?
|
| Baroreflex | 2 | 2012 | 53 | 0.170 |
Why?
|
| Physicians | 2 | 2008 | 875 | 0.170 |
Why?
|
| Diabetic Neuropathies | 2 | 2019 | 96 | 0.170 |
Why?
|
| Morphine | 3 | 2018 | 139 | 0.170 |
Why?
|
| Drug Administration Schedule | 6 | 2016 | 766 | 0.170 |
Why?
|
| Ultrasonography | 10 | 2011 | 713 | 0.170 |
Why?
|
| Silicones | 2 | 1997 | 22 | 0.170 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 1221 | 0.170 |
Why?
|
| Epidemiologic Methods | 3 | 1996 | 74 | 0.170 |
Why?
|
| Microbiological Techniques | 1 | 2020 | 30 | 0.170 |
Why?
|
| Stroke Volume | 6 | 2020 | 593 | 0.170 |
Why?
|
| Breast Implants | 2 | 1997 | 20 | 0.160 |
Why?
|
| Carotid Artery, Common | 1 | 2020 | 35 | 0.160 |
Why?
|
| Prognosis | 9 | 2019 | 3773 | 0.160 |
Why?
|
| Behavior Therapy | 4 | 2006 | 241 | 0.160 |
Why?
|
| Equipment Contamination | 1 | 2020 | 58 | 0.160 |
Why?
|
| Sphygmomanometers | 2 | 2012 | 9 | 0.160 |
Why?
|
| Placebos | 3 | 2009 | 201 | 0.160 |
Why?
|
| Calcium | 2 | 2005 | 1212 | 0.160 |
Why?
|
| Copper | 2 | 2016 | 108 | 0.160 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 84 | 0.160 |
Why?
|
| Eggs | 2 | 2018 | 25 | 0.160 |
Why?
|
| Social Class | 5 | 2018 | 259 | 0.160 |
Why?
|
| Image Enhancement | 2 | 1997 | 168 | 0.160 |
Why?
|
| Emigration and Immigration | 1 | 2000 | 49 | 0.160 |
Why?
|
| Disease Outbreaks | 1 | 2002 | 349 | 0.160 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2003 | 530 | 0.160 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 1 | 2019 | 9 | 0.160 |
Why?
|
| Graft Rejection | 3 | 1997 | 598 | 0.160 |
Why?
|
| Volunteers | 1 | 2019 | 29 | 0.160 |
Why?
|
| Food Contamination | 1 | 2019 | 44 | 0.160 |
Why?
|
| Smokers | 1 | 2020 | 140 | 0.160 |
Why?
|
| Pilot Projects | 3 | 2020 | 1597 | 0.150 |
Why?
|
| Puberty, Precocious | 1 | 2018 | 13 | 0.150 |
Why?
|
| Vitamins | 2 | 2012 | 173 | 0.150 |
Why?
|
| Food Assistance | 1 | 2019 | 29 | 0.150 |
Why?
|
| Competency-Based Education | 2 | 2016 | 71 | 0.150 |
Why?
|
| Surface Properties | 3 | 2016 | 400 | 0.150 |
Why?
|
| Global Health | 2 | 2020 | 329 | 0.150 |
Why?
|
| Social Media | 2 | 2019 | 141 | 0.150 |
Why?
|
| C-Reactive Protein | 3 | 2012 | 401 | 0.150 |
Why?
|
| Donor Selection | 1 | 2019 | 75 | 0.150 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2012 | 56 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 739 | 0.150 |
Why?
|
| Receptors, Opioid, mu | 2 | 2016 | 66 | 0.150 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 376 | 0.150 |
Why?
|
| Pharmacology | 1 | 2018 | 9 | 0.150 |
Why?
|
| Body Fat Distribution | 2 | 2010 | 49 | 0.150 |
Why?
|
| Socioeconomic Factors | 6 | 2015 | 1214 | 0.150 |
Why?
|
| Hemofiltration | 1 | 1998 | 30 | 0.150 |
Why?
|
| Photoelectron Spectroscopy | 2 | 2016 | 6 | 0.150 |
Why?
|
| Clinical Competence | 5 | 2016 | 1020 | 0.150 |
Why?
|
| Biosensing Techniques | 2 | 2010 | 118 | 0.150 |
Why?
|
| Sex Distribution | 4 | 2010 | 359 | 0.150 |
Why?
|
| Executive Function | 2 | 2024 | 433 | 0.150 |
Why?
|
| Potassium, Dietary | 2 | 2015 | 11 | 0.150 |
Why?
|
| Health Education | 5 | 2013 | 335 | 0.150 |
Why?
|
| Bupropion | 1 | 2018 | 40 | 0.150 |
Why?
|
| Coronary Vessels | 2 | 2018 | 239 | 0.150 |
Why?
|
| School Health Services | 3 | 2013 | 234 | 0.150 |
Why?
|
| Postoperative Care | 2 | 2005 | 244 | 0.150 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 205 | 0.140 |
Why?
|
| Biochemistry | 1 | 2018 | 38 | 0.140 |
Why?
|
| Microscopy, Atomic Force | 2 | 2016 | 118 | 0.140 |
Why?
|
| Smoking Cessation | 2 | 2020 | 409 | 0.140 |
Why?
|
| Glutathione | 1 | 1999 | 349 | 0.140 |
Why?
|
| Zinc | 1 | 2001 | 286 | 0.140 |
Why?
|
| Survival Rate | 3 | 2020 | 1872 | 0.140 |
Why?
|
| Education, Medical, Continuing | 2 | 2016 | 123 | 0.140 |
Why?
|
| Bacteria | 3 | 2024 | 814 | 0.140 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 229 | 0.140 |
Why?
|
| Seasons | 2 | 2014 | 493 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2020 | 256 | 0.140 |
Why?
|
| Communicable Disease Control | 1 | 2018 | 75 | 0.140 |
Why?
|
| Pulmonary Valve Stenosis | 1 | 1997 | 18 | 0.140 |
Why?
|
| Spores, Bacterial | 2 | 2014 | 18 | 0.140 |
Why?
|
| Costs and Cost Analysis | 2 | 2018 | 201 | 0.140 |
Why?
|
| Portion Size | 1 | 2017 | 6 | 0.140 |
Why?
|
| Endothelium, Vascular | 5 | 2018 | 902 | 0.140 |
Why?
|
| Blood Flow Velocity | 7 | 2011 | 406 | 0.140 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2018 | 509 | 0.140 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2019 | 534 | 0.140 |
Why?
|
| Role | 1 | 1997 | 32 | 0.140 |
Why?
|
| Naltrexone | 1 | 2018 | 87 | 0.140 |
Why?
|
| Chronic Disease | 5 | 2017 | 1724 | 0.140 |
Why?
|
| Electrocardiography | 6 | 2009 | 613 | 0.140 |
Why?
|
| Heart Transplantation | 5 | 2007 | 722 | 0.140 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 226 | 0.140 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2012 | 53 | 0.130 |
Why?
|
| Dobutamine | 1 | 1997 | 37 | 0.130 |
Why?
|
| World Health Organization | 3 | 2014 | 110 | 0.130 |
Why?
|
| Disease Susceptibility | 2 | 2009 | 334 | 0.130 |
Why?
|
| History, 20th Century | 3 | 2019 | 295 | 0.130 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2018 | 573 | 0.130 |
Why?
|
| Toothache | 1 | 2016 | 5 | 0.130 |
Why?
|
| Pregnancy in Diabetics | 1 | 2018 | 118 | 0.130 |
Why?
|
| Probability | 4 | 2009 | 304 | 0.130 |
Why?
|
| Insurance, Health | 2 | 2009 | 269 | 0.130 |
Why?
|
| Acute Disease | 3 | 2009 | 980 | 0.130 |
Why?
|
| Mindfulness | 1 | 2018 | 116 | 0.130 |
Why?
|
| Algorithms | 4 | 2009 | 1617 | 0.130 |
Why?
|
| Vascular Diseases | 3 | 2010 | 240 | 0.130 |
Why?
|
| Psoriasis | 1 | 2017 | 87 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2019 | 357 | 0.130 |
Why?
|
| Health Personnel | 3 | 2013 | 658 | 0.130 |
Why?
|
| Argon | 1 | 2016 | 21 | 0.130 |
Why?
|
| Autonomic Nervous System | 2 | 2013 | 75 | 0.130 |
Why?
|
| Molar, Third | 3 | 2012 | 6 | 0.130 |
Why?
|
| Referral and Consultation | 4 | 2020 | 735 | 0.120 |
Why?
|
| Odds Ratio | 7 | 2011 | 1022 | 0.120 |
Why?
|
| Elasticity | 3 | 2011 | 195 | 0.120 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 202 | 0.120 |
Why?
|
| Internship and Residency | 4 | 2015 | 1058 | 0.120 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2016 | 41 | 0.120 |
Why?
|
| Heart Failure | 9 | 2008 | 2148 | 0.120 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 258 | 0.120 |
Why?
|
| Mammaplasty | 1 | 1997 | 101 | 0.120 |
Why?
|
| Body Size | 2 | 2014 | 103 | 0.120 |
Why?
|
| Tetrahydroisoquinolines | 2 | 2007 | 8 | 0.120 |
Why?
|
| Blood Pressure Monitors | 1 | 2015 | 3 | 0.120 |
Why?
|
| Policy Making | 1 | 2016 | 89 | 0.120 |
Why?
|
| Diet Surveys | 3 | 2020 | 92 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 3 | 2006 | 711 | 0.120 |
Why?
|
| Colectomy | 1 | 2016 | 93 | 0.120 |
Why?
|
| Models, Theoretical | 2 | 2009 | 549 | 0.120 |
Why?
|
| Hygiene | 1 | 2015 | 29 | 0.120 |
Why?
|
| Aged, 80 and over | 10 | 2013 | 7066 | 0.120 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 1996 | 121 | 0.120 |
Why?
|
| Xenopus | 1 | 1995 | 85 | 0.120 |
Why?
|
| Cross-Over Studies | 4 | 2012 | 521 | 0.120 |
Why?
|
| Family Relations | 1 | 2016 | 87 | 0.120 |
Why?
|
| Glucose | 2 | 2023 | 1003 | 0.120 |
Why?
|
| Suburban Population | 3 | 2006 | 16 | 0.120 |
Why?
|
| National Institutes of Health (U.S.) | 6 | 2016 | 122 | 0.120 |
Why?
|
| Thiophenes | 1 | 2016 | 117 | 0.120 |
Why?
|
| Physical Therapy Modalities | 1 | 2018 | 296 | 0.120 |
Why?
|
| Drug Combinations | 4 | 2022 | 331 | 0.120 |
Why?
|
| Critical Care | 1 | 2020 | 552 | 0.120 |
Why?
|
| Decontamination | 3 | 2022 | 24 | 0.120 |
Why?
|
| Analysis of Variance | 3 | 2013 | 1291 | 0.120 |
Why?
|
| Cardiac Volume | 2 | 2005 | 12 | 0.120 |
Why?
|
| Polycystic Ovary Syndrome | 3 | 2015 | 164 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2005 | 3397 | 0.120 |
Why?
|
| Medical Informatics | 1 | 2016 | 99 | 0.120 |
Why?
|
| Reye Syndrome | 2 | 1985 | 4 | 0.120 |
Why?
|
| Fructose | 1 | 2015 | 108 | 0.110 |
Why?
|
| Blood Coagulation | 2 | 2014 | 239 | 0.110 |
Why?
|
| Confidence Intervals | 4 | 2010 | 318 | 0.110 |
Why?
|
| Salicylates | 2 | 1985 | 30 | 0.110 |
Why?
|
| Interior Design and Furnishings | 1 | 2014 | 4 | 0.110 |
Why?
|
| Social Welfare | 1 | 2014 | 26 | 0.110 |
Why?
|
| Recurrence | 3 | 2008 | 1013 | 0.110 |
Why?
|
| Eyelashes | 1 | 2014 | 4 | 0.110 |
Why?
|
| Creatine | 2 | 1998 | 58 | 0.110 |
Why?
|
| Menstrual Cycle | 2 | 2015 | 121 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 580 | 0.110 |
Why?
|
| Silicon Dioxide | 1 | 2015 | 109 | 0.110 |
Why?
|
| Cloprostenol | 1 | 2014 | 13 | 0.110 |
Why?
|
| Family Practice | 3 | 2003 | 456 | 0.110 |
Why?
|
| Intergenerational Relations | 1 | 2014 | 22 | 0.110 |
Why?
|
| Periodicals as Topic | 1 | 1997 | 204 | 0.110 |
Why?
|
| Television | 2 | 2019 | 74 | 0.110 |
Why?
|
| Platelet Count | 1 | 2014 | 82 | 0.110 |
Why?
|
| Florida | 2 | 2013 | 93 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 277 | 0.110 |
Why?
|
| Learning | 1 | 2018 | 403 | 0.110 |
Why?
|
| Infant Nutritional Physiological Phenomena | 2 | 2006 | 137 | 0.110 |
Why?
|
| beta-Lactamases | 1 | 2014 | 41 | 0.110 |
Why?
|
| Bacteriological Techniques | 1 | 2014 | 70 | 0.110 |
Why?
|
| Immunoassay | 2 | 2015 | 108 | 0.110 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2014 | 34 | 0.110 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 212 | 0.110 |
Why?
|
| Phenotype | 3 | 2019 | 3062 | 0.110 |
Why?
|
| Child Health Services | 2 | 2016 | 184 | 0.110 |
Why?
|
| Ophthalmic Solutions | 1 | 2014 | 75 | 0.110 |
Why?
|
| Combined Modality Therapy | 6 | 2017 | 1201 | 0.110 |
Why?
|
| Personality Inventory | 2 | 1997 | 139 | 0.110 |
Why?
|
| Lipoproteins, HDL | 3 | 2016 | 85 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 241 | 0.110 |
Why?
|
| Fibrinogen | 1 | 2014 | 164 | 0.110 |
Why?
|
| Nanoparticles | 2 | 2015 | 376 | 0.110 |
Why?
|
| Helium | 1 | 2013 | 6 | 0.110 |
Why?
|
| Amides | 1 | 2014 | 91 | 0.110 |
Why?
|
| Tachycardia, Supraventricular | 1 | 1994 | 44 | 0.110 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 313 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 347 | 0.110 |
Why?
|
| Alcoholic Intoxication | 1 | 1994 | 64 | 0.100 |
Why?
|
| Air | 1 | 2013 | 35 | 0.100 |
Why?
|
| Melatonin | 2 | 2004 | 125 | 0.100 |
Why?
|
| Physicians, Women | 1 | 2014 | 72 | 0.100 |
Why?
|
| Hyperglycemia | 2 | 2014 | 327 | 0.100 |
Why?
|
| Surface-Active Agents | 2 | 2015 | 86 | 0.100 |
Why?
|
| Administrative Personnel | 1 | 2013 | 30 | 0.100 |
Why?
|
| Amines | 2 | 2010 | 37 | 0.100 |
Why?
|
| Retinal Diseases | 4 | 2001 | 87 | 0.100 |
Why?
|
| Administration, Oral | 3 | 2012 | 787 | 0.100 |
Why?
|
| Specimen Handling | 1 | 2014 | 163 | 0.100 |
Why?
|
| Urban Health | 2 | 2012 | 79 | 0.100 |
Why?
|
| History, 21st Century | 2 | 2018 | 186 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 1274 | 0.100 |
Why?
|
| Immunoglobulin G | 3 | 2015 | 851 | 0.100 |
Why?
|
| Plasma | 1 | 2014 | 206 | 0.100 |
Why?
|
| Animals | 9 | 2019 | 35409 | 0.100 |
Why?
|
| Minerals | 1 | 2012 | 40 | 0.100 |
Why?
|
| Public Health Practice | 1 | 2013 | 64 | 0.100 |
Why?
|
| Coagulants | 1 | 2012 | 15 | 0.100 |
Why?
|
| Nutritional Physiological Phenomena | 3 | 2001 | 53 | 0.100 |
Why?
|
| Fellowships and Scholarships | 2 | 2015 | 279 | 0.100 |
Why?
|
| Femoral Artery | 1 | 2013 | 174 | 0.100 |
Why?
|
| Epidemiological Monitoring | 1 | 2012 | 50 | 0.100 |
Why?
|
| Apolipoprotein A-I | 1 | 2012 | 28 | 0.100 |
Why?
|
| Patient Education as Topic | 3 | 2012 | 743 | 0.100 |
Why?
|
| Suburban Health | 1 | 2012 | 2 | 0.100 |
Why?
|
| Minority Groups | 2 | 2023 | 250 | 0.100 |
Why?
|
| National Health Programs | 1 | 2012 | 17 | 0.100 |
Why?
|
| Cause of Death | 1 | 2014 | 395 | 0.100 |
Why?
|
| Coronary Artery Disease | 3 | 2011 | 680 | 0.100 |
Why?
|
| Blood Coagulation Tests | 1 | 2012 | 60 | 0.100 |
Why?
|
| Neoplasms | 4 | 2021 | 2454 | 0.100 |
Why?
|
| Adenosine | 1 | 1994 | 227 | 0.100 |
Why?
|
| Glycemic Index | 1 | 2012 | 25 | 0.100 |
Why?
|
| Blood Platelets | 2 | 2014 | 386 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2016 | 385 | 0.100 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1994 | 176 | 0.090 |
Why?
|
| Poverty | 1 | 2016 | 499 | 0.090 |
Why?
|
| Mercury | 1 | 2012 | 41 | 0.090 |
Why?
|
| Calcinosis | 2 | 2011 | 233 | 0.090 |
Why?
|
| Factor VIII | 1 | 2012 | 87 | 0.090 |
Why?
|
| Ligation | 2 | 2009 | 87 | 0.090 |
Why?
|
| Blood Vessels | 2 | 2005 | 187 | 0.090 |
Why?
|
| Hospital Departments | 1 | 2011 | 10 | 0.090 |
Why?
|
| Observer Variation | 5 | 2012 | 314 | 0.090 |
Why?
|
| Least-Squares Analysis | 2 | 2008 | 79 | 0.090 |
Why?
|
| Smoking Prevention | 1 | 2012 | 164 | 0.090 |
Why?
|
| Cultural Diversity | 2 | 2023 | 63 | 0.090 |
Why?
|
| Ventricular Function | 3 | 2000 | 61 | 0.090 |
Why?
|
| Hostility | 2 | 2010 | 14 | 0.090 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2011 | 6 | 0.090 |
Why?
|
| Household Products | 1 | 1991 | 6 | 0.090 |
Why?
|
| Health Services Research | 1 | 2014 | 392 | 0.090 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 190 | 0.090 |
Why?
|
| Infection Control | 1 | 2012 | 143 | 0.090 |
Why?
|
| Community Health Services | 1 | 2013 | 229 | 0.090 |
Why?
|
| Health Planning Councils | 2 | 2008 | 6 | 0.090 |
Why?
|
| Detergents | 1 | 1991 | 44 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2012 | 233 | 0.090 |
Why?
|
| Household Articles | 1 | 1991 | 24 | 0.090 |
Why?
|
| Infant, Premature | 2 | 1992 | 541 | 0.090 |
Why?
|
| Brain Ischemia | 2 | 2019 | 321 | 0.090 |
Why?
|
| Insulin-Secreting Cells | 1 | 2015 | 367 | 0.090 |
Why?
|
| Erythrocytes | 2 | 1998 | 673 | 0.090 |
Why?
|
| Rest | 3 | 2001 | 120 | 0.090 |
Why?
|
| Reactive Oxygen Species | 2 | 2024 | 592 | 0.090 |
Why?
|
| Survivors | 2 | 2011 | 464 | 0.090 |
Why?
|
| Obesity, Abdominal | 1 | 2010 | 47 | 0.090 |
Why?
|
| Cycloparaffins | 1 | 2010 | 2 | 0.090 |
Why?
|
| Microchip Analytical Procedures | 1 | 2010 | 5 | 0.090 |
Why?
|
| Environmental Exposure | 2 | 2011 | 463 | 0.090 |
Why?
|
| Connective Tissue Diseases | 2 | 1994 | 82 | 0.080 |
Why?
|
| Postoperative Period | 3 | 2008 | 330 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 337 | 0.080 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2010 | 42 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 508 | 0.080 |
Why?
|
| Polyenes | 1 | 2010 | 16 | 0.080 |
Why?
|
| Attitude | 2 | 1989 | 254 | 0.080 |
Why?
|
| Silver Sulfadiazine | 1 | 1989 | 1 | 0.080 |
Why?
|
| Sulfadiazine | 1 | 1989 | 4 | 0.080 |
Why?
|
| Ethanol | 1 | 1994 | 591 | 0.080 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1989 | 41 | 0.080 |
Why?
|
| Dosage Forms | 1 | 2009 | 12 | 0.080 |
Why?
|
| Acrylates | 1 | 1989 | 46 | 0.080 |
Why?
|
| Alcoholism | 2 | 2005 | 766 | 0.080 |
Why?
|
| Editorial Policies | 1 | 2010 | 48 | 0.080 |
Why?
|
| Parenting | 1 | 2013 | 294 | 0.080 |
Why?
|
| Electronic Health Records | 2 | 2017 | 979 | 0.080 |
Why?
|
| Epiphyses, Slipped | 1 | 2009 | 4 | 0.080 |
Why?
|
| Basal Metabolism | 2 | 2002 | 58 | 0.080 |
Why?
|
| Peritoneal Dialysis | 2 | 2001 | 95 | 0.080 |
Why?
|
| Growth | 2 | 2002 | 59 | 0.080 |
Why?
|
| Tooth, Impacted | 1 | 2009 | 8 | 0.080 |
Why?
|
| Therapeutic Equivalency | 1 | 2009 | 30 | 0.080 |
Why?
|
| Staphylococcus aureus | 1 | 2013 | 436 | 0.080 |
Why?
|
| Oxygen | 2 | 2022 | 916 | 0.080 |
Why?
|
| Disinfectants | 2 | 2023 | 35 | 0.080 |
Why?
|
| Diet Therapy | 2 | 2017 | 34 | 0.080 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2008 | 6 | 0.080 |
Why?
|
| Atrial Function | 2 | 2006 | 11 | 0.080 |
Why?
|
| Methacrylates | 1 | 1989 | 113 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2012 | 367 | 0.080 |
Why?
|
| Sample Size | 1 | 2009 | 116 | 0.080 |
Why?
|
| Carotid Stenosis | 1 | 2009 | 84 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 231 | 0.080 |
Why?
|
| Anion Exchange Resins | 1 | 2008 | 7 | 0.080 |
Why?
|
| Sleep Apnea, Central | 1 | 2008 | 11 | 0.080 |
Why?
|
| Homeostasis | 2 | 2009 | 605 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 1 | 2009 | 176 | 0.070 |
Why?
|
| Anastomosis, Roux-en-Y | 2 | 2005 | 27 | 0.070 |
Why?
|
| Diagnostic Errors | 2 | 2007 | 162 | 0.070 |
Why?
|
| Glucose Intolerance | 1 | 2010 | 142 | 0.070 |
Why?
|
| Niacin | 1 | 2008 | 19 | 0.070 |
Why?
|
| Publishing | 1 | 2010 | 140 | 0.070 |
Why?
|
| Arm | 2 | 2010 | 107 | 0.070 |
Why?
|
| Pregnancy in Adolescence | 1 | 2009 | 80 | 0.070 |
Why?
|
| Students | 2 | 2011 | 582 | 0.070 |
Why?
|
| Microbial Viability | 2 | 2022 | 83 | 0.070 |
Why?
|
| Drug Utilization | 1 | 2009 | 171 | 0.070 |
Why?
|
| Digestive System Diseases | 1 | 2008 | 26 | 0.070 |
Why?
|
| Hypertension, Renovascular | 1 | 1987 | 15 | 0.070 |
Why?
|
| Intracranial Hemorrhages | 1 | 2008 | 78 | 0.070 |
Why?
|
| Fatty Acids | 2 | 2001 | 427 | 0.070 |
Why?
|
| Culture | 1 | 2008 | 124 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 401 | 0.070 |
Why?
|
| Leadership | 1 | 2012 | 361 | 0.070 |
Why?
|
| Arousal | 2 | 2004 | 150 | 0.070 |
Why?
|
| Dioxoles | 1 | 2007 | 9 | 0.070 |
Why?
|
| Ifosfamide | 1 | 2007 | 34 | 0.070 |
Why?
|
| Signal Detection, Psychological | 1 | 2007 | 24 | 0.070 |
Why?
|
| Hypothalamic Diseases | 1 | 2007 | 18 | 0.070 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2005 | 97 | 0.070 |
Why?
|
| Prescription Drugs | 1 | 2009 | 112 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 252 | 0.070 |
Why?
|
| Models, Animal | 1 | 2009 | 376 | 0.070 |
Why?
|
| Physical Examination | 1 | 2009 | 234 | 0.070 |
Why?
|
| Anthracyclines | 1 | 2007 | 49 | 0.070 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2007 | 13 | 0.070 |
Why?
|
| Cerebrovascular Disorders | 3 | 1982 | 90 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2010 | 231 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2007 | 67 | 0.070 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 672 | 0.070 |
Why?
|
| Leg | 2 | 2010 | 240 | 0.070 |
Why?
|
| Endocardium | 2 | 1997 | 33 | 0.070 |
Why?
|
| Texas | 1 | 2007 | 237 | 0.070 |
Why?
|
| Syndrome | 2 | 2004 | 338 | 0.070 |
Why?
|
| Trace Elements | 1 | 2007 | 49 | 0.070 |
Why?
|
| Carrier Proteins | 2 | 2002 | 741 | 0.070 |
Why?
|
| Informed Consent | 2 | 2006 | 165 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 326 | 0.070 |
Why?
|
| Echocardiography, Doppler | 4 | 1998 | 108 | 0.070 |
Why?
|
| Pulsatile Flow | 3 | 2011 | 60 | 0.070 |
Why?
|
| Kidney | 2 | 1994 | 1383 | 0.060 |
Why?
|
| Compliance | 2 | 2004 | 44 | 0.060 |
Why?
|
| Perioperative Care | 2 | 2006 | 166 | 0.060 |
Why?
|
| Craniopharyngioma | 1 | 2007 | 74 | 0.060 |
Why?
|
| Urban Population | 3 | 2005 | 443 | 0.060 |
Why?
|
| Mitral Valve | 2 | 2005 | 86 | 0.060 |
Why?
|
| Drinking Behavior | 1 | 2006 | 11 | 0.060 |
Why?
|
| Seizures | 1 | 1989 | 402 | 0.060 |
Why?
|
| Healthy People Programs | 1 | 2006 | 8 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2008 | 1042 | 0.060 |
Why?
|
| Polymers | 1 | 2010 | 479 | 0.060 |
Why?
|
| Publication Bias | 1 | 2006 | 35 | 0.060 |
Why?
|
| Aortic Valve Stenosis | 2 | 1988 | 219 | 0.060 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2006 | 30 | 0.060 |
Why?
|
| Waiting Lists | 1 | 2008 | 238 | 0.060 |
Why?
|
| Virginia | 1 | 2005 | 60 | 0.060 |
Why?
|
| Peer Review, Research | 1 | 2006 | 41 | 0.060 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 64 | 0.060 |
Why?
|
| Social Environment | 1 | 2007 | 293 | 0.060 |
Why?
|
| Inflammation | 3 | 2012 | 2748 | 0.060 |
Why?
|
| Pituitary Neoplasms | 1 | 2007 | 180 | 0.060 |
Why?
|
| Infant Food | 1 | 2006 | 65 | 0.060 |
Why?
|
| Social Adjustment | 1 | 2005 | 57 | 0.060 |
Why?
|
| Program Development | 1 | 2007 | 355 | 0.060 |
Why?
|
| Psychology, Social | 1 | 2005 | 12 | 0.060 |
Why?
|
| Body Weights and Measures | 1 | 2005 | 35 | 0.060 |
Why?
|
| Sulfones | 2 | 2003 | 108 | 0.060 |
Why?
|
| Educational Measurement | 2 | 2015 | 264 | 0.060 |
Why?
|
| Psychology | 1 | 2005 | 81 | 0.060 |
Why?
|
| Serum Amyloid A Protein | 1 | 2005 | 31 | 0.060 |
Why?
|
| Sarcoma | 1 | 2007 | 175 | 0.060 |
Why?
|
| Tonsillitis | 1 | 2004 | 6 | 0.060 |
Why?
|
| Adenoids | 1 | 2004 | 12 | 0.060 |
Why?
|
| Dietary Fiber | 1 | 2005 | 51 | 0.060 |
Why?
|
| Hypercalcemia | 1 | 1985 | 21 | 0.060 |
Why?
|
| Hospitals, Pediatric | 3 | 2005 | 517 | 0.060 |
Why?
|
| Musculoskeletal Diseases | 1 | 2006 | 69 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2005 | 80 | 0.060 |
Why?
|
| Amlodipine | 1 | 2004 | 10 | 0.060 |
Why?
|
| Personality Assessment | 1 | 2004 | 81 | 0.060 |
Why?
|
| Hyperphagia | 1 | 2004 | 34 | 0.060 |
Why?
|
| Reward | 2 | 2018 | 243 | 0.060 |
Why?
|
| Internal-External Control | 1 | 2004 | 69 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 1989 | 612 | 0.060 |
Why?
|
| Mental Competency | 1 | 2004 | 25 | 0.060 |
Why?
|
| Cardiomegaly | 3 | 1991 | 172 | 0.060 |
Why?
|
| Parental Consent | 1 | 2004 | 25 | 0.060 |
Why?
|
| Milk, Human | 1 | 2006 | 151 | 0.060 |
Why?
|
| Likelihood Functions | 1 | 2004 | 137 | 0.060 |
Why?
|
| Respiratory Tract Diseases | 1 | 2006 | 149 | 0.060 |
Why?
|
| Haplotypes | 1 | 2006 | 474 | 0.060 |
Why?
|
| Factor Analysis, Statistical | 1 | 2005 | 284 | 0.060 |
Why?
|
| Respiration Disorders | 1 | 2004 | 72 | 0.050 |
Why?
|
| Diagnosis, Differential | 5 | 2005 | 1434 | 0.050 |
Why?
|
| Oxyhemoglobins | 1 | 2004 | 21 | 0.050 |
Why?
|
| Temperament | 1 | 2004 | 46 | 0.050 |
Why?
|
| Smoke | 1 | 2005 | 140 | 0.050 |
Why?
|
| Heart Function Tests | 1 | 2004 | 59 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2011 | 833 | 0.050 |
Why?
|
| Twins | 1 | 2005 | 247 | 0.050 |
Why?
|
| Colony Count, Microbial | 2 | 2015 | 118 | 0.050 |
Why?
|
| Blood Gas Analysis | 1 | 2004 | 73 | 0.050 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2004 | 102 | 0.050 |
Why?
|
| Sampling Studies | 2 | 2000 | 96 | 0.050 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 235 | 0.050 |
Why?
|
| Creatinine | 2 | 2022 | 490 | 0.050 |
Why?
|
| Reactive Nitrogen Species | 1 | 2023 | 21 | 0.050 |
Why?
|
| General Surgery | 1 | 2005 | 152 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 161 | 0.050 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 1984 | 86 | 0.050 |
Why?
|
| Dyspepsia | 1 | 2003 | 10 | 0.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 1993 | 286 | 0.050 |
Why?
|
| Renin | 2 | 1993 | 32 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 2009 | 395 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 373 | 0.050 |
Why?
|
| Mother-Child Relations | 1 | 2004 | 133 | 0.050 |
Why?
|
| Epidemiology | 1 | 1983 | 15 | 0.050 |
Why?
|
| Mental Disorders | 2 | 2005 | 1035 | 0.050 |
Why?
|
| Air Microbiology | 1 | 2023 | 40 | 0.050 |
Why?
|
| ROC Curve | 2 | 2011 | 504 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2003 | 42 | 0.050 |
Why?
|
| Contraception | 2 | 2011 | 153 | 0.050 |
Why?
|
| Community Health Planning | 1 | 2003 | 42 | 0.050 |
Why?
|
| Bandages, Hydrocolloid | 1 | 2002 | 1 | 0.050 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 1999 | 381 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 836 | 0.050 |
Why?
|
| Infant Welfare | 1 | 2002 | 9 | 0.050 |
Why?
|
| Infant, Premature, Diseases | 1 | 1984 | 93 | 0.050 |
Why?
|
| Delayed-Action Preparations | 2 | 2016 | 174 | 0.050 |
Why?
|
| Goals | 2 | 2015 | 163 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2006 | 367 | 0.050 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 1982 | 7 | 0.050 |
Why?
|
| Faculty | 1 | 2023 | 138 | 0.050 |
Why?
|
| Self-Help Groups | 2 | 2005 | 34 | 0.050 |
Why?
|
| Analgesia | 1 | 2003 | 104 | 0.050 |
Why?
|
| Educational Status | 4 | 2006 | 474 | 0.050 |
Why?
|
| Lipoprotein(a) | 1 | 2022 | 67 | 0.050 |
Why?
|
| Ocular Hypotension | 1 | 2001 | 10 | 0.050 |
Why?
|
| Iowa | 1 | 2021 | 24 | 0.050 |
Why?
|
| Models, Biological | 1 | 2009 | 1724 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 104 | 0.050 |
Why?
|
| Ciliary Body | 1 | 2001 | 33 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 422 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2005 | 521 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2021 | 50 | 0.050 |
Why?
|
| Eye Injuries | 1 | 2001 | 46 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2018 | 2403 | 0.040 |
Why?
|
| Registries | 2 | 2007 | 1903 | 0.040 |
Why?
|
| Heart Septal Defects, Ventricular | 2 | 1991 | 41 | 0.040 |
Why?
|
| Hypertrichosis | 1 | 2001 | 7 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2001 | 76 | 0.040 |
Why?
|
| Lip | 1 | 2001 | 21 | 0.040 |
Why?
|
| Attention | 1 | 2024 | 439 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2004 | 709 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2002 | 149 | 0.040 |
Why?
|
| Gravidity | 2 | 2011 | 7 | 0.040 |
Why?
|
| Curriculum | 3 | 2015 | 928 | 0.040 |
Why?
|
| Health | 1 | 2001 | 75 | 0.040 |
Why?
|
| Nutritional Sciences | 1 | 2001 | 43 | 0.040 |
Why?
|
| Religion and Psychology | 1 | 1980 | 27 | 0.040 |
Why?
|
| Rats | 1 | 2009 | 5487 | 0.040 |
Why?
|
| Delivery of Health Care | 2 | 2024 | 900 | 0.040 |
Why?
|
| Safety | 1 | 2002 | 335 | 0.040 |
Why?
|
| Hair | 1 | 2001 | 73 | 0.040 |
Why?
|
| Cataract Extraction | 1 | 2001 | 97 | 0.040 |
Why?
|
| Bacteria, Aerobic | 1 | 2020 | 7 | 0.040 |
Why?
|
| Attitude to Death | 1 | 1980 | 67 | 0.040 |
Why?
|
| Parity | 2 | 2011 | 121 | 0.040 |
Why?
|
| Mississippi | 1 | 2000 | 21 | 0.040 |
Why?
|
| Vietnam | 1 | 2000 | 26 | 0.040 |
Why?
|
| Chi-Square Distribution | 3 | 2014 | 515 | 0.040 |
Why?
|
| Water | 1 | 2023 | 442 | 0.040 |
Why?
|
| Biofilms | 1 | 2022 | 245 | 0.040 |
Why?
|
| Culturally Competent Care | 1 | 2020 | 57 | 0.040 |
Why?
|
| Gastric Emptying | 1 | 2000 | 39 | 0.040 |
Why?
|
| Medicaid | 1 | 2004 | 433 | 0.040 |
Why?
|
| Wound Healing | 1 | 2002 | 308 | 0.040 |
Why?
|
| Pyridines | 1 | 2003 | 478 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2002 | 247 | 0.040 |
Why?
|
| Stomach | 1 | 2000 | 109 | 0.040 |
Why?
|
| Visual Acuity | 1 | 2001 | 326 | 0.040 |
Why?
|
| Association | 1 | 2019 | 12 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2018 | 2703 | 0.040 |
Why?
|
| Homocysteine | 1 | 1999 | 152 | 0.040 |
Why?
|
| Lactones | 1 | 1999 | 55 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2000 | 137 | 0.040 |
Why?
|
| Breast | 2 | 2003 | 140 | 0.040 |
Why?
|
| Polyradiculoneuropathy | 1 | 1998 | 3 | 0.040 |
Why?
|
| Purine-Pyrimidine Metabolism, Inborn Errors | 1 | 1998 | 2 | 0.040 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2018 | 13 | 0.040 |
Why?
|
| Adenosine Deaminase | 1 | 1998 | 29 | 0.040 |
Why?
|
| Education | 1 | 2019 | 104 | 0.040 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 1998 | 20 | 0.040 |
Why?
|
| Neuropharmacology | 1 | 2018 | 5 | 0.040 |
Why?
|
| Exercise Therapy | 2 | 2017 | 413 | 0.040 |
Why?
|
| Oxidative Stress | 2 | 2008 | 1264 | 0.040 |
Why?
|
| Switzerland | 1 | 2018 | 36 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2000 | 224 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 2 | 1998 | 203 | 0.040 |
Why?
|
| England | 1 | 2018 | 74 | 0.040 |
Why?
|
| Endothelins | 1 | 2018 | 62 | 0.040 |
Why?
|
| Postmenopause | 1 | 2000 | 349 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 2 | 2012 | 117 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2001 | 291 | 0.040 |
Why?
|
| Echocardiography, Transesophageal | 1 | 1998 | 93 | 0.040 |
Why?
|
| Half-Life | 2 | 2012 | 162 | 0.040 |
Why?
|
| Self Administration | 1 | 2018 | 122 | 0.040 |
Why?
|
| Fluorescein Angiography | 2 | 2001 | 143 | 0.040 |
Why?
|
| Lipoproteins, LDL | 3 | 2008 | 127 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2012 | 306 | 0.040 |
Why?
|
| Glycemic Load | 1 | 2017 | 1 | 0.040 |
Why?
|
| Sulfhydryl Compounds | 1 | 1999 | 187 | 0.030 |
Why?
|
| Edible Grain | 2 | 2012 | 48 | 0.030 |
Why?
|
| Occupational Health | 2 | 2013 | 193 | 0.030 |
Why?
|
| Random Allocation | 1 | 2018 | 347 | 0.030 |
Why?
|
| Attitude of Health Personnel | 2 | 2017 | 1106 | 0.030 |
Why?
|
| Liver | 3 | 2015 | 1839 | 0.030 |
Why?
|
| Sodium Chloride | 1 | 1997 | 138 | 0.030 |
Why?
|
| Cognition | 1 | 2024 | 1125 | 0.030 |
Why?
|
| Rheumatic Diseases | 1 | 1997 | 69 | 0.030 |
Why?
|
| Tablets | 1 | 2016 | 35 | 0.030 |
Why?
|
| Cholestyramine Resin | 1 | 1996 | 7 | 0.030 |
Why?
|
| Contraindications | 2 | 2007 | 90 | 0.030 |
Why?
|
| Munchausen Syndrome by Proxy | 1 | 1996 | 2 | 0.030 |
Why?
|
| Ipecac | 1 | 1996 | 8 | 0.030 |
Why?
|
| Specialty Boards | 1 | 2016 | 32 | 0.030 |
Why?
|
| Norepinephrine | 2 | 1987 | 209 | 0.030 |
Why?
|
| Self-Control | 1 | 2017 | 55 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2017 | 60 | 0.030 |
Why?
|
| Automation | 1 | 1996 | 81 | 0.030 |
Why?
|
| Equipment Design | 2 | 2010 | 514 | 0.030 |
Why?
|
| Aminosalicylic Acids | 1 | 1996 | 5 | 0.030 |
Why?
|
| Proteins | 1 | 2002 | 944 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 827 | 0.030 |
Why?
|
| Minority Health | 1 | 2016 | 20 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 1997 | 136 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 1999 | 1031 | 0.030 |
Why?
|
| Selection Bias | 1 | 1995 | 37 | 0.030 |
Why?
|
| Dietary Proteins | 2 | 2011 | 129 | 0.030 |
Why?
|
| Enema | 1 | 1996 | 43 | 0.030 |
Why?
|
| Rural Population | 1 | 2000 | 521 | 0.030 |
Why?
|
| Prednisolone | 1 | 1996 | 82 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1997 | 397 | 0.030 |
Why?
|
| Light | 2 | 2015 | 363 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2002 | 1119 | 0.030 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2015 | 5 | 0.030 |
Why?
|
| Nuclear Transfer Techniques | 1 | 1995 | 2 | 0.030 |
Why?
|
| Patients' Rooms | 1 | 2015 | 12 | 0.030 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2015 | 22 | 0.030 |
Why?
|
| Physicians' Offices | 1 | 1995 | 17 | 0.030 |
Why?
|
| Professional-Patient Relations | 1 | 2016 | 140 | 0.030 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2015 | 84 | 0.030 |
Why?
|
| Polysorbates | 1 | 2015 | 40 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2005 | 2511 | 0.030 |
Why?
|
| Hyperlipoproteinemias | 2 | 2007 | 7 | 0.030 |
Why?
|
| Serum Albumin, Bovine | 1 | 2015 | 63 | 0.030 |
Why?
|
| Ankle Brachial Index | 1 | 2015 | 36 | 0.030 |
Why?
|
| Scattering, Radiation | 1 | 2015 | 100 | 0.030 |
Why?
|
| Reoperation | 1 | 1997 | 542 | 0.030 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2015 | 47 | 0.030 |
Why?
|
| Tobacco Products | 1 | 2016 | 110 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 2 | 2008 | 253 | 0.030 |
Why?
|
| Freeze Drying | 1 | 2015 | 82 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 249 | 0.030 |
Why?
|
| Immunization | 1 | 1997 | 411 | 0.030 |
Why?
|
| Lipid Metabolism | 2 | 2010 | 503 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 165 | 0.030 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2015 | 91 | 0.030 |
Why?
|
| Breast Diseases | 1 | 1994 | 22 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 1996 | 120 | 0.030 |
Why?
|
| Behavior, Addictive | 1 | 2015 | 81 | 0.030 |
Why?
|
| Cholesterol, Dietary | 2 | 2007 | 18 | 0.030 |
Why?
|
| Thrombopoiesis | 1 | 2014 | 8 | 0.030 |
Why?
|
| Methicillin Resistance | 1 | 2014 | 18 | 0.030 |
Why?
|
| Bimatoprost | 1 | 2014 | 3 | 0.030 |
Why?
|
| Lymphoscintigraphy | 1 | 1994 | 9 | 0.030 |
Why?
|
| Fontan Procedure | 1 | 1996 | 175 | 0.030 |
Why?
|
| Nonverbal Communication | 1 | 1994 | 4 | 0.030 |
Why?
|
| Mutation | 2 | 2011 | 3706 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2015 | 355 | 0.030 |
Why?
|
| Ventricular Function, Right | 1 | 1996 | 276 | 0.030 |
Why?
|
| Quinolines | 1 | 2015 | 156 | 0.030 |
Why?
|
| Gene Expression | 2 | 1998 | 1465 | 0.030 |
Why?
|
| Taste | 1 | 1996 | 225 | 0.030 |
Why?
|
| Esthetics | 1 | 2014 | 49 | 0.030 |
Why?
|
| Mice | 2 | 2009 | 16983 | 0.030 |
Why?
|
| Particle Size | 1 | 2015 | 355 | 0.030 |
Why?
|
| Quality Control | 1 | 2014 | 162 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 177 | 0.030 |
Why?
|
| Heart Block | 1 | 1994 | 40 | 0.030 |
Why?
|
| Capsules | 1 | 2013 | 42 | 0.030 |
Why?
|
| Visual Analog Scale | 1 | 2013 | 30 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 1708 | 0.030 |
Why?
|
| Biomedical Technology | 1 | 2014 | 42 | 0.030 |
Why?
|
| Writing | 1 | 2015 | 91 | 0.030 |
Why?
|
| DNA Replication | 1 | 1995 | 225 | 0.030 |
Why?
|
| Anxiety | 1 | 1980 | 976 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2018 | 606 | 0.030 |
Why?
|
| Canada | 2 | 2008 | 353 | 0.030 |
Why?
|
| Glass | 1 | 2013 | 43 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2013 | 67 | 0.030 |
Why?
|
| Catecholamines | 1 | 1993 | 96 | 0.030 |
Why?
|
| Cardiac Output, Low | 1 | 1993 | 66 | 0.030 |
Why?
|
| Length of Stay | 2 | 1998 | 1133 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2004 | 306 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2010 | 1271 | 0.030 |
Why?
|
| Fibromyalgia | 1 | 1993 | 56 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1994 | 437 | 0.030 |
Why?
|
| Cardiac Catheterization | 3 | 1991 | 520 | 0.020 |
Why?
|
| Genetic Carrier Screening | 1 | 2012 | 26 | 0.020 |
Why?
|
| Teaching | 1 | 2015 | 218 | 0.020 |
Why?
|
| Debridement | 1 | 1993 | 83 | 0.020 |
Why?
|
| Coronary Vessel Anomalies | 2 | 1991 | 33 | 0.020 |
Why?
|
| International System of Units | 1 | 2012 | 2 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 1993 | 60 | 0.020 |
Why?
|
| Clinical Clerkship | 1 | 1994 | 96 | 0.020 |
Why?
|
| Catheterization | 1 | 1993 | 176 | 0.020 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1992 | 51 | 0.020 |
Why?
|
| Poultry | 1 | 2012 | 9 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 1996 | 340 | 0.020 |
Why?
|
| Alpha-Globulins | 1 | 1992 | 20 | 0.020 |
Why?
|
| Transferrin | 1 | 1992 | 42 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1995 | 583 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2005 | 813 | 0.020 |
Why?
|
| Hyaluronic Acid | 1 | 1994 | 216 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1996 | 482 | 0.020 |
Why?
|
| Radionuclide Imaging | 2 | 2000 | 122 | 0.020 |
Why?
|
| Interleukin-6 | 2 | 2012 | 724 | 0.020 |
Why?
|
| Biopsy | 2 | 2006 | 1089 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1995 | 590 | 0.020 |
Why?
|
| Fathers | 1 | 2012 | 50 | 0.020 |
Why?
|
| Career Choice | 1 | 2014 | 206 | 0.020 |
Why?
|
| Absorption | 1 | 2012 | 59 | 0.020 |
Why?
|
| Aspirin | 2 | 2003 | 380 | 0.020 |
Why?
|
| Calibration | 1 | 2012 | 140 | 0.020 |
Why?
|
| Digoxin | 1 | 1991 | 28 | 0.020 |
Why?
|
| Income | 2 | 2003 | 188 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 156 | 0.020 |
Why?
|
| Hot Temperature | 2 | 2010 | 369 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2018 | 680 | 0.020 |
Why?
|
| Pulse | 2 | 2006 | 23 | 0.020 |
Why?
|
| Magnesium | 2 | 2007 | 155 | 0.020 |
Why?
|
| Isoenzymes | 1 | 1992 | 301 | 0.020 |
Why?
|
| Fishes | 1 | 2012 | 94 | 0.020 |
Why?
|
| Social Responsibility | 1 | 2012 | 47 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2012 | 107 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1686 | 0.020 |
Why?
|
| Causality | 1 | 2012 | 117 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 3 | 1993 | 176 | 0.020 |
Why?
|
| Societies | 1 | 2011 | 39 | 0.020 |
Why?
|
| Inservice Training | 1 | 2012 | 111 | 0.020 |
Why?
|
| Leptin | 1 | 2012 | 222 | 0.020 |
Why?
|
| Hyperaldosteronism | 1 | 2011 | 8 | 0.020 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2011 | 6 | 0.020 |
Why?
|
| Proprotein Convertases | 1 | 2011 | 15 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2012 | 349 | 0.020 |
Why?
|
| Albuminuria | 1 | 1992 | 183 | 0.020 |
Why?
|
| Fundus Oculi | 1 | 1991 | 61 | 0.020 |
Why?
|
| Actigraphy | 1 | 2011 | 98 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 175 | 0.020 |
Why?
|
| beta-Cyclodextrins | 1 | 2011 | 27 | 0.020 |
Why?
|
| Gestational Age | 2 | 2011 | 876 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 195 | 0.020 |
Why?
|
| Photography | 1 | 1991 | 93 | 0.020 |
Why?
|
| Emotions | 1 | 2016 | 545 | 0.020 |
Why?
|
| Ethylenediamines | 1 | 2010 | 6 | 0.020 |
Why?
|
| Wettability | 1 | 2010 | 13 | 0.020 |
Why?
|
| Propylamines | 1 | 2010 | 11 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2011 | 120 | 0.020 |
Why?
|
| Silanes | 1 | 2010 | 18 | 0.020 |
Why?
|
| Schools, Medical | 1 | 2011 | 136 | 0.020 |
Why?
|
| Food Handling | 1 | 2010 | 60 | 0.020 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2010 | 81 | 0.020 |
Why?
|
| Vaccines | 1 | 1995 | 400 | 0.020 |
Why?
|
| Sign Language | 1 | 1989 | 3 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 25 | 0.020 |
Why?
|
| Type A Personality | 1 | 1989 | 2 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2010 | 206 | 0.020 |
Why?
|
| New York City | 2 | 2004 | 81 | 0.020 |
Why?
|
| Italy | 2 | 2004 | 99 | 0.020 |
Why?
|
| Cooking | 1 | 2010 | 59 | 0.020 |
Why?
|
| Environment | 1 | 2012 | 345 | 0.020 |
Why?
|
| Gases | 1 | 2010 | 44 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 522 | 0.020 |
Why?
|
| Adhesiveness | 1 | 1989 | 20 | 0.020 |
Why?
|
| Occlusive Dressings | 1 | 1989 | 5 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2010 | 73 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 639 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1989 | 82 | 0.020 |
Why?
|
| Heart Septum | 2 | 2004 | 27 | 0.020 |
Why?
|
| Oscillometry | 1 | 2009 | 37 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2010 | 130 | 0.020 |
Why?
|
| Manometry | 1 | 2009 | 92 | 0.020 |
Why?
|
| Students, Medical | 1 | 1994 | 323 | 0.020 |
Why?
|
| Risk Management | 1 | 2010 | 92 | 0.020 |
Why?
|
| DNA, Single-Stranded | 1 | 2010 | 114 | 0.020 |
Why?
|
| Malnutrition | 1 | 2010 | 79 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2009 | 118 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 1994 | 544 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2008 | 27 | 0.020 |
Why?
|
| Fistula | 1 | 1989 | 35 | 0.020 |
Why?
|
| South Carolina | 1 | 2008 | 40 | 0.020 |
Why?
|
| Voluntary Health Agencies | 1 | 2008 | 5 | 0.020 |
Why?
|
| Professional Staff Committees | 1 | 2008 | 13 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 2545 | 0.020 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1988 | 56 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 577 | 0.020 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2011 | 179 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 1992 | 284 | 0.020 |
Why?
|
| Moyamoya Disease | 1 | 2008 | 19 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 851 | 0.020 |
Why?
|
| Intracranial Embolism | 1 | 2008 | 31 | 0.020 |
Why?
|
| Nutrition Therapy | 1 | 2008 | 32 | 0.020 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 1988 | 4 | 0.020 |
Why?
|
| Hemoglobins | 2 | 1989 | 339 | 0.020 |
Why?
|
| Physical Exertion | 1 | 1989 | 210 | 0.020 |
Why?
|
| Georgia | 1 | 1988 | 80 | 0.020 |
Why?
|
| Fibromuscular Dysplasia | 1 | 1987 | 7 | 0.020 |
Why?
|
| Pulmonary Veins | 1 | 1989 | 98 | 0.020 |
Why?
|
| Psychometrics | 2 | 1989 | 701 | 0.020 |
Why?
|
| Failure to Thrive | 1 | 1987 | 29 | 0.020 |
Why?
|
| Medical Audit | 1 | 2008 | 74 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2010 | 348 | 0.020 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2008 | 78 | 0.020 |
Why?
|
| Arteritis | 1 | 1987 | 26 | 0.020 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 1989 | 137 | 0.020 |
Why?
|
| Hypopituitarism | 1 | 2007 | 16 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2009 | 234 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 2008 | 174 | 0.020 |
Why?
|
| Nutritive Value | 1 | 2007 | 36 | 0.020 |
Why?
|
| Vitamin A | 1 | 2007 | 55 | 0.020 |
Why?
|
| Neurofibromatosis 1 | 1 | 1987 | 50 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 433 | 0.020 |
Why?
|
| Melanoma | 1 | 1994 | 730 | 0.020 |
Why?
|
| Nursing | 1 | 2007 | 35 | 0.020 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2008 | 179 | 0.020 |
Why?
|
| Pulmonary Circulation | 2 | 1991 | 431 | 0.020 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 1988 | 132 | 0.020 |
Why?
|
| Angioplasty, Balloon | 1 | 1987 | 92 | 0.020 |
Why?
|
| HIV Protease Inhibitors | 1 | 2007 | 68 | 0.020 |
Why?
|
| United Kingdom | 1 | 2007 | 258 | 0.020 |
Why?
|
| Mass Media | 1 | 2006 | 40 | 0.020 |
Why?
|
| Phytotherapy | 1 | 2007 | 79 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 1269 | 0.020 |
Why?
|
| Interpersonal Relations | 2 | 2006 | 395 | 0.020 |
Why?
|
| Tachycardia | 1 | 2006 | 57 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 177 | 0.020 |
Why?
|
| Aneurysm | 1 | 1986 | 31 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 1204 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 322 | 0.020 |
Why?
|
| Hepatitis | 1 | 2006 | 47 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 2007 | 164 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 647 | 0.020 |
Why?
|
| DNA | 1 | 1992 | 1406 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 1987 | 175 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 1326 | 0.010 |
Why?
|
| Genotype | 2 | 2002 | 1829 | 0.010 |
Why?
|
| Retinal Artery | 1 | 1985 | 16 | 0.010 |
Why?
|
| Radiography | 1 | 1987 | 800 | 0.010 |
Why?
|
| Panic Disorder | 1 | 2005 | 23 | 0.010 |
Why?
|
| Cerebral Angiography | 2 | 1982 | 108 | 0.010 |
Why?
|
| Phobic Disorders | 1 | 2005 | 31 | 0.010 |
Why?
|
| Achievement | 1 | 2005 | 57 | 0.010 |
Why?
|
| Cotinine | 1 | 2005 | 75 | 0.010 |
Why?
|
| Renal Artery Obstruction | 1 | 1985 | 29 | 0.010 |
Why?
|
| Sutures | 1 | 2005 | 53 | 0.010 |
Why?
|
| Consensus | 1 | 2008 | 622 | 0.010 |
Why?
|
| Food Services | 1 | 2004 | 19 | 0.010 |
Why?
|
| Workplace | 1 | 2006 | 247 | 0.010 |
Why?
|
| Intestinal Obstruction | 1 | 2005 | 49 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2006 | 254 | 0.010 |
Why?
|
| Child Care | 1 | 2004 | 26 | 0.010 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2004 | 46 | 0.010 |
Why?
|
| Physical Education and Training | 1 | 2004 | 75 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 287 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2006 | 247 | 0.010 |
Why?
|
| Blood Volume | 1 | 1984 | 61 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 2004 | 83 | 0.010 |
Why?
|
| Vitamin D | 1 | 2007 | 380 | 0.010 |
Why?
|
| Mexican Americans | 1 | 2005 | 113 | 0.010 |
Why?
|
| Physical Endurance | 1 | 2005 | 264 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2006 | 281 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2008 | 637 | 0.010 |
Why?
|
| Aortic Diseases | 1 | 1985 | 114 | 0.010 |
Why?
|
| Stomach Diseases | 1 | 2003 | 20 | 0.010 |
Why?
|
| Face | 1 | 1985 | 165 | 0.010 |
Why?
|
| Helicobacter Infections | 1 | 2003 | 29 | 0.010 |
Why?
|
| Peptic Ulcer | 1 | 2003 | 18 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1989 | 763 | 0.010 |
Why?
|
| Helicobacter pylori | 1 | 2003 | 38 | 0.010 |
Why?
|
| Genitalia, Female | 1 | 2003 | 38 | 0.010 |
Why?
|
| Wakefulness | 1 | 2004 | 120 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2007 | 532 | 0.010 |
Why?
|
| Esophagitis | 1 | 2003 | 67 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2005 | 337 | 0.010 |
Why?
|
| Publications | 1 | 2003 | 41 | 0.010 |
Why?
|
| Biological Availability | 1 | 2003 | 147 | 0.010 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 72 | 0.010 |
Why?
|
| Uncoupling Protein 3 | 1 | 2002 | 8 | 0.010 |
Why?
|
| Uncoupling Protein 1 | 1 | 2002 | 15 | 0.010 |
Why?
|
| Uncoupling Protein 2 | 1 | 2002 | 8 | 0.010 |
Why?
|
| Testosterone | 1 | 2005 | 372 | 0.010 |
Why?
|
| Calorimetry, Indirect | 1 | 2002 | 81 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 198 | 0.010 |
Why?
|
| Laser Coagulation | 1 | 2001 | 57 | 0.010 |
Why?
|
| Ion Channels | 1 | 2002 | 133 | 0.010 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2001 | 59 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 1213 | 0.010 |
Why?
|
| Hypoxia | 1 | 2008 | 1087 | 0.010 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2003 | 219 | 0.010 |
Why?
|
| Plant Oils | 1 | 2001 | 29 | 0.010 |
Why?
|
| Fish Oils | 1 | 2001 | 27 | 0.010 |
Why?
|
| Coronary Angiography | 3 | 1989 | 306 | 0.010 |
Why?
|
| Barrett Esophagus | 1 | 2003 | 148 | 0.010 |
Why?
|
| Fish Products | 1 | 2000 | 7 | 0.010 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2000 | 23 | 0.010 |
Why?
|
| Software | 1 | 2005 | 608 | 0.010 |
Why?
|
| Hemostasis | 1 | 2001 | 80 | 0.010 |
Why?
|
| Women's Health | 1 | 2003 | 364 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2000 | 6 | 0.010 |
Why?
|
| North Carolina | 1 | 2000 | 99 | 0.010 |
Why?
|
| Tropomodulin | 1 | 1999 | 2 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 494 | 0.010 |
Why?
|
| Intraocular Pressure | 1 | 2001 | 299 | 0.010 |
Why?
|
| Medical Records | 1 | 2000 | 171 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1999 | 306 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2000 | 168 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 1999 | 128 | 0.010 |
Why?
|
| Adenine Nucleotides | 1 | 1998 | 22 | 0.010 |
Why?
|
| Mental Health | 1 | 2005 | 691 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2005 | 711 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 1998 | 58 | 0.010 |
Why?
|
| Louisiana | 1 | 1998 | 27 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2006 | 2062 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2006 | 1098 | 0.010 |
Why?
|
| Body Surface Area | 1 | 1997 | 33 | 0.010 |
Why?
|
| Pedigree | 2 | 1992 | 483 | 0.010 |
Why?
|
| Emetine | 1 | 1996 | 6 | 0.010 |
Why?
|
| Administration, Rectal | 1 | 1996 | 11 | 0.010 |
Why?
|
| Mesalamine | 1 | 1996 | 10 | 0.010 |
Why?
|
| Thermometers | 1 | 1995 | 8 | 0.010 |
Why?
|
| Alleles | 1 | 1998 | 843 | 0.010 |
Why?
|
| Group Practice | 1 | 1995 | 7 | 0.010 |
Why?
|
| Refrigeration | 1 | 1995 | 11 | 0.010 |
Why?
|
| Medical Staff | 1 | 1995 | 16 | 0.010 |
Why?
|
| Private Practice | 1 | 1995 | 21 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1996 | 300 | 0.010 |
Why?
|
| Poisoning | 1 | 1996 | 111 | 0.010 |
Why?
|
| Ontario | 1 | 1995 | 90 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 1644 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1996 | 271 | 0.010 |
Why?
|
| Drug Storage | 1 | 1995 | 58 | 0.010 |
Why?
|
| Remission Induction | 1 | 1996 | 274 | 0.010 |
Why?
|
| Steroids | 1 | 1996 | 158 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 1999 | 2135 | 0.010 |
Why?
|
| Videotape Recording | 1 | 1994 | 34 | 0.010 |
Why?
|
| Proteinuria | 1 | 1994 | 91 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 1995 | 338 | 0.010 |
Why?
|
| Interview, Psychological | 1 | 1994 | 93 | 0.010 |
Why?
|
| Cations | 1 | 1994 | 80 | 0.010 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 1973 | 19 | 0.010 |
Why?
|
| Thiopental | 1 | 1993 | 4 | 0.010 |
Why?
|
| Enflurane | 1 | 1993 | 3 | 0.010 |
Why?
|
| Premedication | 1 | 1993 | 42 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 1994 | 320 | 0.010 |
Why?
|
| Nitrous Oxide | 1 | 1993 | 32 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1992 | 64 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 66 | 0.010 |
Why?
|
| HIV Infections | 1 | 2007 | 2730 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1992 | 188 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 1992 | 109 | 0.010 |
Why?
|
| Myocarditis | 1 | 1993 | 98 | 0.010 |
Why?
|
| Asthma | 1 | 2005 | 2225 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1995 | 1199 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1992 | 296 | 0.010 |
Why?
|
| Sports Medicine | 1 | 1973 | 110 | 0.010 |
Why?
|
| Diuretics | 1 | 1991 | 76 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 1992 | 134 | 0.010 |
Why?
|
| Eosinophilia | 1 | 1993 | 204 | 0.010 |
Why?
|
| Respiration | 1 | 1991 | 193 | 0.010 |
Why?
|
| Personality Tests | 1 | 1989 | 15 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 1992 | 467 | 0.010 |
Why?
|
| Triage | 1 | 1991 | 207 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1991 | 234 | 0.000 |
Why?
|
| Color | 1 | 1989 | 73 | 0.000 |
Why?
|
| Hospitalization | 1 | 1998 | 2079 | 0.000 |
Why?
|
| Aorta | 1 | 1991 | 408 | 0.000 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1994 | 1058 | 0.000 |
Why?
|
| Osmolar Concentration | 1 | 1987 | 167 | 0.000 |
Why?
|
| Peer Group | 1 | 1989 | 227 | 0.000 |
Why?
|
| Cyanosis | 1 | 1987 | 16 | 0.000 |
Why?
|
| Posture | 1 | 1988 | 175 | 0.000 |
Why?
|
| Macrophages | 1 | 1994 | 1489 | 0.000 |
Why?
|
| Signal Transduction | 1 | 1999 | 4935 | 0.000 |
Why?
|
| Airway Obstruction | 1 | 1987 | 154 | 0.000 |
Why?
|
| Pulmonary Artery | 1 | 1991 | 1097 | 0.000 |
Why?
|
| Hemiplegia | 1 | 1982 | 21 | 0.000 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1982 | 80 | 0.000 |
Why?
|